RxDoctor Payments Data

Dinesh Bhatt, MD

Cardiovascular Disease · Panama City, FLNPI 1053408815

Payments from drug & device makers

$682in general payments, 2019–2025

Across 30 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$213
  • Vifor Pharma, Inc.$158
  • Novartis$68
  • Pfizer$66
  • Biotronik Inc.$56
  • Boston Scientific$55
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$67298%
  • Education$112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$682 in reported general payments places this provider in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$16,520
Medicare patients
48
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$117,120
EntrestoSacubitril/Valsartan77$95,549
JardianceEmpagliflozin25$21,297
Ranolazine ErRanolazine13$2,400
Nebivolol Hcl20$1,814
Propafenone Hcl15$1,409
SotalolSotalol Hcl54$1,270
Metoprolol Succinate67$789
Sildenafil Citrate13$788
Digoxin13$569
Isosorbide Mononitrate ErIsosorbide Mononitrate35$459
Spironolactone-HctzSpironolact/Hydrochlorothiazid15$440
Carvedilol36$428
Atorvastatin Calcium48$408
Spironolactone29$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$117,12098 claims
NovartisEntresto$68$95,54977 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →